Apurano Pharmaceuticals GmbH
đ©đȘGermany
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Phase 3
Recruiting
- Conditions
- Peripheral NeuralgiaPeripheral NeuropathyPainPain SyndromePain, ChronicDiabetesPeripheral Neuropathy With Type 2 DiabetisChronic PainChronic Pain SyndromeDiabetic Neuropathies
- Interventions
- Drug: Adezunap (AP707)Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06072573
- Locations
- đ©đȘ
Klinikum Rechts der Isar (Zentrum fĂŒr InterdisziplinĂ€re Schmerztherapie), Munich, Bavaria, Germany
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Phase 3
Recruiting
- Conditions
- Neuropathic PainPeripheral NeuropathyPainPain SyndromePain, ChronicChronic PainPost-Traumatic NeuralgiaChronic Pain SyndromePeripheral Nerve InjuryPost Operative Pain
- Interventions
- Drug: Adezunap (AP707)Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06071936
- Locations
- đ©đȘ
Klinikum Rechts der Isar (Zentrum fĂŒr InterdisziplinĂ€re Schmerztherapie), Munich, Bavaria, Germany
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Phase 3
Recruiting
- Conditions
- Pain SyndromeChronic PainPainPain, ChronicLower Back PainChronic Pain SyndromeBack PainLower Back Pain Chronic
- Interventions
- Drug: PlaceboDrug: Adezunap (AP707)
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06071962
- Locations
- đ©đȘ
Klinikum Rechts der Isar (Zentrum fĂŒr InterdisziplinĂ€re Schmerztherapie), Munich, Bavaria, Germany
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Phase 3
Recruiting
- Conditions
- Pain SyndromeCentral Neuropathic PainPhantom Limb Syndrome With PainPainChronic Pain SyndromePhantom PainTraumatic Brain InjuryPain, ChronicChronic PainNeuropathic Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06071949
- Locations
- đ©đȘ
Klinikum Rechts der Isar (Zentrum fĂŒr InterdisziplinĂ€re Schmerztherapie), Munich, Bavaria, Germany
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Phase 3
Recruiting
- Conditions
- Pain SyndromePeripheral NeuropathyChronic PainChronic Pain SyndromeDiabetic NeuropathiesPeripheral NeuralgiaDiabetesDiabetic PolyneuropathyPeripheral Neuropathy With Type 2 DiabetisPain
- Interventions
- Drug: Adezunap (AP707)Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06071975
- Locations
- đ©đȘ
Klinikum Rechts der Isar (Zentrum fĂŒr InterdisziplinĂ€re Schmerztherapie), Munich, Bavaria, Germany
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Phase 3
Recruiting
- Conditions
- PainChronic PainPain SyndromePain, ChronicPost-Traumatic NeuralgiaChronic Pain SyndromePeripheral NeuropathyPeripheral Nerve InjuryPost Operative PainPlexopathy
- Interventions
- Drug: Adezunap (AP707)Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06071988
- Locations
- đ©đȘ
Klinikum Rechts der Isar (Zentrum fĂŒr InterdisziplinĂ€re Schmerztherapie), Munich, Bavaria, Germany
Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Phase 3
Recruiting
- Conditions
- Pain, ChronicLower Back PainPainPain SyndromeLower Back Pain ChronicChronic PainChronic Pain SyndromeBack Pain
- Interventions
- Drug: PlaceboDrug: Adezunap (AP707)
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06072560
- Locations
- đ©đȘ
Klinikum Rechts der Isar (Zentrum fĂŒr InterdisziplinĂ€re Schmerztherapie), Munich, Bavaria, Germany
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Phase 3
Recruiting
- Conditions
- Neuropathic PainParaplegiaPhantom PainPain, ChronicStrokeChronic PainCentral Neuropathic PainMultiple SclerosisTraumatic Brain InjuryChronic Pain Syndrome
- Interventions
- Drug: PlaceboDrug: Adezunap (AP707)
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Apurano Pharmaceuticals GmbH
- Target Recruit Count
- 558
- Registration Number
- NCT06072001
- Locations
- đ©đȘ
Klinikum Rechts der Isar (Zentrum fĂŒr InterdisziplinĂ€re Schmerztherapie), Munich, Bavaria, Germany
© Copyright 2025. All Rights Reserved by MedPath